Sign in or create an account to add this stock to your watchlist.
About Bristol-Myers Squibb (NYSE:BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic collaboration agreement with Nektar Therapeutics, Illumina, Inc., and Janssen Pharmaceuticals, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:BMY
CUSIP11012210
Phone212-546-4000
Debt
Debt-to-Equity Ratio0.45
Current Ratio1.52
Quick Ratio1.39
Price-To-Earnings
Trailing P/E Ratio17.53
Forward P/E Ratio15.48
P/E Growth1.32
Sales & Book Value
Annual Sales$20.78 billion
Price / Sales4.15
Cash Flow$3.5369 per share
Price / Cash14.92
Book Value$7.90 per share
Price / Book6.68
Profitability
EPS (Most Recent Fiscal Year)$3.01
Net Income$1.01 billion
Net Margins4.37%
Return on Equity37.56%
Return on Assets15.27%
Miscellaneous
Employees23,700
Outstanding Shares1,634,540,000
Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions
What is Bristol-Myers Squibb's stock symbol?
Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."
How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?
Bristol-Myers Squibb declared a quarterly dividend on Thursday, March 1st. Shareholders of record on Friday, April 6th will be paid a dividend of $0.40 per share on Tuesday, May 1st. This represents a $1.60 annualized dividend and a yield of 3.03%. The ex-dividend date is Thursday, April 5th. View Bristol-Myers Squibb's Dividend History.
How were Bristol-Myers Squibb's earnings last quarter?
Bristol-Myers Squibb Co (NYSE:BMY) posted its quarterly earnings results on Thursday, April, 26th. The biopharmaceutical company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.09. The biopharmaceutical company earned $5.19 billion during the quarter, compared to analyst estimates of $5.25 billion. Bristol-Myers Squibb had a net margin of 4.37% and a return on equity of 37.56%. Bristol-Myers Squibb's revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter last year, the business earned $0.84 earnings per share. View Bristol-Myers Squibb's Earnings History.
When is Bristol-Myers Squibb's next earnings date?
What guidance has Bristol-Myers Squibb issued on next quarter's earnings?
Bristol-Myers Squibb updated its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share guidance of $3.35-3.45 for the period, compared to the Thomson Reuters consensus estimate of $3.26.
What price target have analysts set for BMY?
19 equities research analysts have issued 1 year price targets for Bristol-Myers Squibb's shares. Their predictions range from $47.00 to $78.00. On average, they expect Bristol-Myers Squibb's stock price to reach $62.6519 in the next year. View Analyst Ratings for Bristol-Myers Squibb.
Are investors shorting Bristol-Myers Squibb?
Bristol-Myers Squibb saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 14,317,338 shares, an increase of 28.5% from the March 30th total of 11,139,095 shares. Based on an average trading volume of 7,952,211 shares, the days-to-cover ratio is presently 1.8 days. Approximately 0.9% of the shares of the stock are sold short.
Who are some of Bristol-Myers Squibb's key competitors?
Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Merck & Co. (MRK), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).
Who are Bristol-Myers Squibb's key executives?
Bristol-Myers Squibb's management team includes the folowing people:
- Dr. Giovanni Caforio, Chairman & CEO (Age 53)
- Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 58)
- Dr. Thomas J. Lynch Jr., Exec. VP of R&D & Chief Scientific Officer (Age 57)
- Ms. Sandra Leung, Exec. VP & Gen. Counsel (Age 57)
- Mr. Murdo Gordon, Exec. VP & Chief Commercial Officer (Age 51)
Has Bristol-Myers Squibb been receiving favorable news coverage?
Media headlines about BMY stock have been trending positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 0.28 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 44.41 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Bristol-Myers Squibb's major shareholders?
Bristol-Myers Squibb's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.39%), Northern Trust Corp (1.40%), Loomis Sayles & Co. L P (0.82%), Legal & General Group Plc (0.49%), Massachusetts Financial Services Co. MA (0.41%) and Schwab Charles Investment Management Inc. (0.37%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Louis S Schmukler, Sandra Leung, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb.
Which institutional investors are selling Bristol-Myers Squibb stock?
BMY stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Northern Trust Corp, Swiss National Bank, Prudential Financial Inc., OppenheimerFunds Inc., Manning & Napier Group LLC, Legal & General Group Plc and State of Tennessee Treasury Department. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Joseph C Caldarella, Sandra Leung and Thomas J Jr Lynch. View Insider Buying and Selling for Bristol-Myers Squibb.
Which institutional investors are buying Bristol-Myers Squibb stock?
BMY stock was acquired by a variety of institutional investors in the last quarter, including Argent Capital Management LLC, Rock Springs Capital Management LP, Massachusetts Financial Services Co. MA, DekaBank Deutsche Girozentrale, Rockefeller Capital Management L.P., Mackay Shields LLC, Summit Trail Advisors LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb.
How do I buy shares of Bristol-Myers Squibb?
Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bristol-Myers Squibb's stock price today?
One share of BMY stock can currently be purchased for approximately $52.77.
How big of a company is Bristol-Myers Squibb?
Bristol-Myers Squibb has a market capitalization of $85.81 billion and generates $20.78 billion in revenue each year. The biopharmaceutical company earns $1.01 billion in net income (profit) each year or $3.01 on an earnings per share basis. Bristol-Myers Squibb employs 23,700 workers across the globe.
How can I contact Bristol-Myers Squibb?
Bristol-Myers Squibb's mailing address is 345 PARK AVE, NEW YORK NY, 10154. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]
MarketBeat Community Rating for Bristol-Myers Squibb (BMY)
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
Bristol-Myers Squibb (NYSE:BMY) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
19 Wall Street analysts have issued ratings and price targets for Bristol-Myers Squibb in the last 12 months. Their average twelve-month price target is $62.6519, suggesting that the stock has a possible upside of 18.73%. The high price target for BMY is $78.00 and the low price target for BMY is $47.00. There are currently 12 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.37 | 2.40 | 2.44 | 2.47 |
| Ratings Breakdown: | 0 Sell Rating(s)
12 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
10 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
7 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $62.6519 | $64.2144 | $66.4615 | $64.50 |
| Price Target Upside: | 18.73% upside | 24.42% upside | 3.65% downside | 7.61% upside |
Bristol-Myers Squibb (NYSE:BMY) Consensus Price Target History
Bristol-Myers Squibb (NYSE:BMY) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Bristol-Myers Squibb (NYSE:BMY) Dividend Information
Bristol-Myers Squibb pays an annual dividend of $1.60 per share, with a dividend yield of 3.03%. BMY's most recent quarterly dividend payment was Tuesday, May 1. The company has grown its dividend for the last 8 consecutive years and is increasing its dividend by an average of 2.70% each year. Bristol-Myers Squibb pays out 53.16% of its earnings out as a dividend.
| Most Recent Dividend: | 5/1/2018 |
| Annual Dividend: | $1.60 |
| Dividend Yield: | 3.03% |
| Dividend Growth: | 2.70% (3 Year Average) |
| Payout Ratio(s): | 53.16% (Trailing 12 Months of Earnings)
46.92% (Based on This Year's Estimates)
43.96% (Based on Next Year's Estimates)
45.24% (Based on Cash Flow)
|
| Track Record: | 8 Years of Consecutive Dividend Growth |
| Frequency: | Quarterly Dividend |
Bristol-Myers Squibb (NYSE:BMY) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 3/1/2018 | quarterly | $0.40 | 2.43568275232151% | 4/5/2018 | 4/6/2018 | 5/1/2018 |
| 12/7/2017 | quarterly | $0.40 | 2.56% | 1/4/2018 | 1/5/2018 | 2/1/2018 |
| 9/13/2017 | quarterly | $0.39 | 2.49% | 10/5/2017 | 10/6/2017 | 11/1/2017 |
| 6/13/2017 | quarterly | $0.39 | 2.86% | 7/5/2017 | 7/7/2017 | 8/1/2017 |
| 3/2/2017 | quarterly | $0.39 | 2.72% | 4/5/2017 | 4/7/2017 | 5/1/2017 |
| 12/8/2016 | quarterly | $0.39 | 2.73% | 1/4/2017 | 1/6/2017 | 2/1/2017 |
| 8/3/2016 | quarterly | $0.38 | 2.02% | 10/5/2016 | 10/7/2016 | 11/1/2016 |
| 6/7/2016 | quarterly | $0.38 | 2.07% | 6/29/2016 | 7/1/2016 | 8/1/2016 |
| 3/3/2016 | quarterly | $0.38 | 2.35% | 3/30/2016 | 4/1/2016 | 5/2/2016 |
| 12/8/2015 | quarterly | $0.38 | 2.22% | 12/30/2015 | 1/4/2016 | 2/1/2016 |
| 9/17/2015 | quarterly | $0.37 | 2.3% | 9/30/2015 | 10/2/2015 | 11/2/2015 |
| 6/16/2015 | quarterly | $0.37 | 2.23% | 7/1/2015 | 7/6/2015 | 8/3/2015 |
| 3/2/2015 | quarterly | $0.37 | 2.39% | 4/1/2015 | 4/6/2015 | 5/1/2015 |
| 12/9/2014 | quarterly | $0.37 | 2.5% | 12/30/2014 | 1/2/2015 | 2/2/2015 |
| 9/16/2014 | quarterly | $0.36 | 2.83% | 10/1/2014 | 10/3/2014 | 11/3/2014 |
| 6/17/2014 | quarterly | $0.36 | 3% | 7/1/2014 | 7/3/2014 | 8/1/2014 |
| 3/3/2014 | quarterly | $0.36 | 2.55% | 4/2/2014 | 4/4/2014 | 5/1/2014 |
| 12/19/2013 | quarterly | $0.36 | 2.7% | 12/31/2013 | 1/3/2014 | 2/3/2014 |
| 9/17/2013 | quarterly | $0.35 | 2.95% | 10/2/2013 | 10/4/2013 | 11/1/2013 |
| 6/19/2013 | quarterly | $0.35 | 3.14% | 7/2/2013 | 7/5/2013 | 8/1/2013 |
| 3/7/2013 | quarterly | $0.35 | 3.74% | 4/3/2013 | 4/5/2013 | 5/1/2013 |
| 12/4/2012 | quarterly | $0.35 | | | 1/4/2013 | 2/1/2013 |
(Data available from 1/1/2013 forward)
Bristol-Myers Squibb (NYSE BMY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 71.29%
Bristol-Myers Squibb (NYSE BMY) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/30/2018 | Dinesh C Paliwal | Director | Buy | 4,770 | $52.40 | $249,948.00 | 8,027 |  |
| 12/15/2017 | Theodore R Samuels II | Director | Buy | 4,000 | $62.30 | $249,200.00 | 22,000 | |
| 12/12/2017 | Thomas J Jr. Lynch | EVP | Sell | 5,300 | $63.24 | $335,172.00 | 9,251 | |
| 12/4/2017 | Sandra Leung | EVP | Sell | 156,582 | $63.37 | $9,922,601.34 | 584,373 | |
| 9/6/2017 | Joseph C Caldarella | SVP | Sell | 9,340 | $60.00 | $560,400.00 | 46,297 | |
| 8/2/2017 | Theodore R Samuels II | Director | Buy | 6,000 | $55.94 | $335,640.00 | 18,000 | |
| 4/7/2017 | Lamberto Andreotti | Director | Sell | 34,000 | $53.26 | $1,810,840.00 | 952,571 | |
| 3/28/2017 | Lamberto Andreotti | Director | Sell | 34,000 | $56.17 | $1,909,780.00 | 986,112 | |
| 3/27/2017 | Lamberto Andreotti | Director | Sell | 17,000 | $56.14 | $954,380.00 | 986,112 | |
| 3/17/2017 | Louis S Schmukler | Insider | Sell | 5,000 | $56.49 | $282,450.00 | 21,483 | |
| 3/15/2017 | Joseph C Caldarella | SVP | Sell | 8,096 | $57.29 | $463,819.84 | 55,637 | |
| 3/6/2017 | Sandra Leung | EVP | Sell | 92,405 | $57.02 | $5,268,933.10 | 488,063 | |
| 2/27/2017 | Theodore R Samuels II | Director | Buy | 12,000 | $56.77 | $681,240.00 | 12,000 | |
| 9/8/2016 | Lamberto Andreotti | Director | Sell | 21,600 | $56.87 | $1,228,392.00 | 334,499 | |
| 8/25/2016 | Lamberto Andreotti | Director | Sell | 23,200 | $59.17 | $1,372,744.00 | 364,999 | |
| 7/8/2016 | Lamberto Andreotti | Director | Sell | 23,200 | $74.45 | $1,727,240.00 | 380,099 | |
| 6/28/2016 | Lamberto Andreotti | Director | Sell | 23,200 | $72.14 | $1,673,648.00 | 403,094 | |
| 6/14/2016 | John E Elicker | SVP | Sell | 11,820 | $72.69 | $859,195.80 | 55,011 | |
| 5/20/2016 | Charles A Bancroft | CFO | Sell | 30,201 | $70.79 | $2,137,928.79 | 184,694 | |
| 5/16/2016 | Joseph C Caldarella | SVP | Sell | 3,519 | $72.47 | $255,021.93 | 55,238 | |
| 5/6/2016 | Sandra Leung | EVP | Sell | 72,544 | $70.39 | $5,106,372.16 | 444,507 | |
| 5/5/2016 | Lamberto Andreotti | Director | Sell | 23,200 | $70.54 | $1,636,528.00 | 425,194 | |
| 5/3/2016 | Giovanni Caforio | CEO | Sell | 34,594 | $71.31 | $2,466,898.14 | 132,263 | |
| 5/2/2016 | Autenried Paul Von | SVP | Sell | 37,258 | $71.93 | $2,679,967.94 | 128,463 | |
| 5/2/2016 | Lamberto Andreotti | Director | Sell | 234,720 | $71.88 | $16,871,673.60 | 536,794 | |
| 5/2/2016 | Louis S Schmukler | Insider | Sell | 22,218 | $71.95 | $1,598,585.10 | 21,971 | |
| 4/5/2016 | Lamberto Andreotti | Director | Sell | 23,200 | $65.90 | $1,528,880.00 | 453,094 | |
| 4/4/2016 | Lamberto Andreotti | Director | Sell | 11,600 | $65.79 | $763,164.00 | 453,094 | |
| 3/9/2016 | Lamberto Andreotti | Director | Sell | 23,200 | $65.71 | $1,524,472.00 | 381,254 | |
| 3/8/2016 | Lewis B Campbell | Director | Sell | 2,500 | $66.00 | $165,000.00 | 2,500 | |
| 3/4/2016 | Joseph C Caldarella | SVP | Sell | 12,962 | $64.64 | $837,863.68 | 46,322 | |
| 2/17/2016 | Giovanni Caforio | CEO | Sell | 12,040 | $63.58 | $765,503.20 | 76,738 | |
| 2/17/2016 | Sandra Leung | EVP | Sell | 10,152 | $63.57 | $645,362.64 | 309,547 | |
| 2/12/2016 | Lamberto Andreotti | Director | Sell | 23,200 | $59.61 | $1,382,952.00 | 392,854 | |
| 1/5/2016 | Lamberto Andreotti | Director | Sell | 23,200 | $67.56 | $1,567,392.00 | 310,424 | |
| 1/4/2016 | Lamberto Andreotti | Director | Sell | 11,600 | $66.93 | $776,388.00 | 310,424 | |
| 12/15/2015 | Lamberto Andreotti | Director | Sell | 23,200 | $69.03 | $1,601,496.00 | 332,852 | |
| 11/20/2015 | Lamberto Andreotti | Director | Sell | 23,200 | $67.39 | $1,563,448.00 | 456,052 | |
| 10/6/2015 | Lamberto Andreotti | Director | Sell | 23,200 | $60.86 | $1,411,952.00 | 524,252 | |
| 9/3/2015 | Lamberto Andreotti | Director | Sell | 23,200 | $59.40 | $1,378,080.00 | 546,874 | |
| 6/4/2015 | Joseph C Caldarella | SVP | Sell | 16,972 | $65.71 | $1,115,230.12 | | |
| 3/16/2015 | Francis M Cuss | EVP | Sell | 114,666 | $67.81 | $7,775,501.46 | | |
| 3/16/2015 | Louis S Schmukler | Insider | Sell | 12,000 | $66.96 | $803,520.00 | | |
| 2/17/2015 | Sandra Leung | General Counsel | Sell | 11,746 | $60.39 | $709,340.94 | | |
| 2/12/2015 | Samuel J Moed | SVP | Sell | 3,880 | $59.26 | $229,928.80 | | |
| 2/6/2015 | Samuel J Moed | SVP | Sell | 21,478 | $60.15 | $1,291,901.70 | | |
| 1/29/2015 | Lamberto Andreotti | CEO | Sell | 90,246 | $61.14 | $5,517,640.44 | | |
| 1/29/2015 | Lewis B Campbell | Director | Sell | 2,500 | $60.89 | $152,225.00 | | |
| 1/29/2015 | Louis S Schmukler | Insider | Sell | 5,250 | $60.73 | $318,832.50 | | |
| 12/5/2014 | Lamberto Andreotti | CEO | Sell | 75,000 | $60.31 | $4,523,250.00 | | |
| 10/24/2014 | Lamberto Andreotti | CEO | Sell | 50,000 | $53.00 | $2,650,000.00 | | |
| 10/6/2014 | Lamberto Andreotti | CEO | Sell | 50,000 | $50.99 | $2,549,500.00 | | |
| 9/16/2014 | Francis M Cuss | EVP | Sell | 63,667 | $50.77 | $3,232,373.59 | | |
| 9/15/2014 | Giovanni Caforio | COO | Sell | 26,691 | $49.87 | $1,331,080.17 | | |
| 9/10/2014 | Joseph C Caldarella | SVP | Sell | 7,415 | $51.03 | $378,387.45 | | |
| 9/8/2014 | Lamberto Andreotti | CEO | Sell | 50,000 | $51.05 | $2,552,500.00 | | |
| 8/19/2014 | Autenried Paul Von | SVP | Sell | 20,000 | $49.89 | $997,800.00 | | |
| 7/29/2014 | Charles A Bancroft | CFO | Sell | 67,621 | $51.06 | $3,452,728.26 | | |
| 7/28/2014 | Samuel J Moed | SVP | Sell | 25,752 | $49.32 | $1,270,088.64 | | |
| 3/13/2014 | Joseph Caldarella | SVP | Sell | 9,137 | $55.20 | $504,362.40 | 68,965 | |
| 3/10/2014 | Lamberto Andreotti | CEO | Sell | 100,000 | $55.52 | $5,552,000.00 | 630,783 | |
| 3/10/2014 | Louis Schmukler | Insider | Sell | 8,799 | $55.81 | $491,072.19 | 8,861 | |
| 3/5/2014 | James Cornelius | Director | Sell | 100,000 | $55.82 | $5,582,000.00 | 273,393 | |
| 2/28/2014 | Louis Schmukler | Insider | Sell | 6,088 | $54.49 | $331,735.12 | 14,696 | |
| 2/24/2014 | Giovanni Caforio | EVP | Sell | 41,563 | $54.44 | $2,262,689.72 | 49,753 | |
| 2/19/2014 | John Elicker | SVP | Sell | 9,534 | $54.22 | $516,933.48 | 32,740 | |
| 2/18/2014 | Francis Cuss | EVP | Sell | 29,800 | $54.61 | $1,627,378.00 | 207,237 | |
| 2/14/2014 | Charles Bancroft | CFO | Sell | 52,963 | $54.35 | $2,878,539.05 | 77,303 | |
| 2/14/2014 | Sandra Leung | General Counsel | Sell | 10,490 | $54.28 | $569,397.20 | 195,855 | |
| 2/11/2014 | Lamberto Andreotti | CEO | Sell | 86,075 | $52.66 | $4,532,709.50 | 500,487 | |
| 2/6/2014 | Joseph Caldarella | SVP | Sell | 35,471 | $48.90 | $1,734,531.90 | 59,355 | |
| 2/5/2014 | Lewis Campbell | Director | Sell | 2,500 | $48.28 | $120,700.00 | | |
| 2/4/2014 | James Cornelius | Director | Sell | 100,000 | $48.90 | $4,890,000.00 | 373,393 | |
| 7/29/2013 | James M Cornelius | Director | Sell | 5,000 | $43.81 | $219,050.00 | | |
| 6/10/2013 | Autenried Paul Von | SVP | Sell | 25,000 | $47.24 | $1,181,000.00 | | |
| 6/6/2013 | Joseph C Caldarella | SVP | Sell | 26,275 | $46.53 | $1,222,575.75 | | |
| 6/5/2013 | John E Elicker | SVP | Sell | 25,997 | $46.33 | $1,204,441.01 | | |
| 6/4/2013 | Lamberto Andreotti | CEO | Sell | 100,000 | $47.74 | $4,774,000.00 | | |
| 6/4/2013 | Samuel J Moed | SVP | Sell | 58,898 | $47.38 | $2,790,587.24 | | |
| 6/3/2013 | Elliot Sigal | EVP | Sell | 83,647 | $48.18 | $4,030,112.46 | | |
| 5/31/2013 | Beatrice J Cazala | EVP | Sell | 91,282 | $47.00 | $4,290,254.00 | | |
| 5/31/2013 | Giovanni Caforio | Insider | Sell | 10,538 | $47.06 | $495,918.28 | | |
| 5/30/2013 | Beatrice J Cazala | EVP | Sell | 22,000 | $47.00 | $1,034,000.00 | | |
| 5/28/2013 | Charles A Bancroft | CFO | Sell | 25,000 | $48.68 | $1,217,000.00 | | |
| 5/28/2013 | James M Cornelius | Director | Sell | 100,000 | $47.61 | $4,761,000.00 | | |
| 5/23/2013 | Beatrice J Cazala | EVP | Sell | 96,000 | $46.99 | $4,511,040.00 | | |
| 5/23/2013 | Giovanni Caforio | Insider | Sell | 26,647 | $46.29 | $1,233,489.63 | | |
| 5/17/2013 | James M Cornelius | Director | Sell | 225,996 | $42.99 | $9,715,568.04 | | |
| 5/8/2013 | James M Cornelius | Director | Sell | 20,000 | $39.85 | $797,000.00 | | |
| 5/2/2013 | James M Cornelius | Director | Sell | 20,000 | $39.76 | $795,200.00 | | |
| 4/11/2013 | James M Cornelius | Director | Sell | 20,000 | $41.15 | $823,000.00 | | |
| 3/13/2013 | James M Cornelius | Director | Sell | 20,000 | $38.18 | $763,600.00 | | |
| 3/13/2013 | John E Elicker | SVP | Sell | 3,409 | $38.51 | $131,280.59 | | |
| 2/27/2013 | Giovanni Caforio | Insider | Sell | 12,150 | $37.08 | $450,522.00 | | |
| 2/26/2013 | James M Cornelius | Director | Sell | 20,000 | $36.58 | $731,600.00 | | |
| 1/17/2013 | James M Cornelius | Director | Sell | 20,000 | $34.33 | $686,600.00 | | |
| 12/28/2012 | James M Cornelius | Director | Sell | 20,000 | $32.06 | $641,200.00 | | |
| 10/3/2012 | James M Cornelius | Director | Sell | 20,000 | $33.71 | $674,200.00 | | |
| 8/10/2012 | James M Cornelius | Director | Sell | 10,000 | $31.81 | $318,100.00 | | |
(Data available from 1/1/2013 forward)
Bristol-Myers Squibb (NYSE BMY) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Label Expansion May Boost Opdivo’s Revenues in 2018
finance.yahoo.com - May 25 at 5:21 PM |
 | Idera to collaborate with Bristol-Myers on study of IMO-2125/Yervoy combo in melanoma; shares up 4% premarket
seekingalpha.com - May 24 at 5:22 PM |
 | Interesting BMY Put And Call Options For July 6th
www.nasdaq.com - May 24 at 5:22 PM |
 | BMS-986231 (Bristol-Myers Squibb/Ligand) Drug Overview 2018: A Second-Generation Prodrug That Chemically Breaks Down to Produce Nitroxyl (HNO) and an Inactive Byproduct ...
www.businesswire.com - May 24 at 8:40 AM |
| Bristol-Myers Squibb to Hold Investor Event to Discuss ASCO Highlights
finance.yahoo.com - May 24 at 8:40 AM |
 | Bristol-Myers Squibb (BMY) Rating Lowered to Hold at UBS
www.americanbankingnews.com - May 21 at 11:05 AM |
| $5.40 Billion in Sales Expected for Bristol-Myers Squibb Co (BMY) This Quarter
www.americanbankingnews.com - May 21 at 3:04 AM |
| 3 Things In Biotech, May 19: Buy BMY? Oncolytics In Again? Atara's Immunotherapy Data
seekingalpha.com - May 20 at 9:00 AM |
| $0.86 EPS Expected for Bristol-Myers Squibb (BMY) This Quarter
www.americanbankingnews.com - May 19 at 1:24 PM |
 | Global Bipolar Disorder Market Growth Opportunities: Sumitomo Dainippon Pharma Co., Allergan, Bristol-Myers Squibb Company
www.marketwatch.com - May 18 at 9:46 AM |
 | Bristol-Myers Squibb (BMY) Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO
www.streetinsider.com - May 17 at 5:14 PM |
| Immunomedics Announces Positive Phase 2 Results
finance.yahoo.com - May 17 at 5:14 PM |
| Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018
finance.yahoo.com - May 16 at 5:21 PM |
| Bristol-Myers Squibb to Take Part in UBS 2018 Global Healthcare Conference
finance.yahoo.com - May 15 at 8:42 AM |
| Exploring Bristol-Myers Squibb’s Financial Performance
finance.yahoo.com - May 15 at 8:42 AM |
| How Bristol-Myers Squibb’s Key Products Performed in 1Q18
finance.yahoo.com - May 14 at 5:13 PM |
| What’s Bristol-Myers Squibb’s Business Strategy?
finance.yahoo.com - May 14 at 5:13 PM |
| Bristol-Myers Squibb (BMY) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 13 at 5:31 PM |
| Eliquis (Apixaban; Bristol-Myers Squibb/Pfizer) Drug Overview 2017/18-2026: An Orally Available Factor Xa Inhibitor Indicated for the Prevention of Venous Thromboembolsim ...
www.businesswire.com - May 11 at 5:35 PM |
| Label Expansion May Boost Keytruda’s Revenue Prospects in 2018
finance.yahoo.com - May 11 at 9:31 AM |
 | Young Lung Cancer Investigators Awarded $200K to Improve Lung Cancer Outcomes
www.prnewswire.com - May 11 at 7:30 AM |
| How Merck’s Animal Health Segment Did in 1Q18
finance.yahoo.com - May 10 at 8:45 AM |
 | Why Bristol-Myers Squibb Stock Crashed in April
www.fool.com - May 9 at 12:58 PM |
| Q4 2018 EPS Estimates for Bristol-Myers Squibb Raised by SunTrust Banks (BMY)
www.americanbankingnews.com - May 9 at 9:06 AM |
| See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.
finance.yahoo.com - May 9 at 8:40 AM |
| New 52-Week Low Could Prompt More Insider Buying At BMY
www.nasdaq.com - May 8 at 5:19 PM |
| Q2 2018 EPS Estimates for Bristol-Myers Squibb Lifted by Analyst (BMY)
www.americanbankingnews.com - May 8 at 5:56 AM |
| Bristol-Myers Squibb Co. (BMY) PT Lowered to $69 at SunTrust Robinson Humphrey
www.streetinsider.com - May 7 at 9:31 AM |
| Allergan’s International Business in 1Q18
finance.yahoo.com - May 7 at 9:31 AM |
| As emergency blood-thinner antidote scores FDA OK, Peninsula drug maker's stock soars
finance.yahoo.com - May 5 at 8:39 AM |
 | BRIEF-EMA Validates Bristol-Myers' Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment ...
www.reuters.com - May 4 at 8:29 AM |
| Bristol-Myers Squibb (BMY) Says EMA Validated its Type II Variation Application for Opdivo Plus Yervoy Combination ...
www.streetinsider.com - May 4 at 8:29 AM |
| BRIEF-Bristol-Myers Squibb Elects Each Of Company's 12 Nominees To Serve As Directors
www.reuters.com - May 4 at 8:29 AM |
| Bristol-Myers Squibb (BMY) Expected to Post Quarterly Sales of $5.38 Billion
www.americanbankingnews.com - May 4 at 4:40 AM |
| Bristol-Myers Squibb (BMY) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - May 3 at 10:32 PM |
| Bristol-Myers to team up with Flatiron Health for an additional three years
seekingalpha.com - May 3 at 8:39 AM |
| Global Polycystic Ovarian Syndrome Treatment Market Competitive landscape: Bristol-Myers Squibb Company
www.marketwatch.com - May 3 at 8:39 AM |
| BRIEF-Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year Agreement
www.reuters.com - May 2 at 5:13 PM |
| Bristol-Myers Squibb (BMY), Flatiron Health Expand Collaboration with Three-Year Agreement
www.streetinsider.com - May 2 at 5:13 PM |
| Comparing BMY’s and LLY’s Valuation
finance.yahoo.com - May 2 at 5:13 PM |
| The Zacks Analyst Blog Highlights: Amazon, Bristol-Myers, Time Warner, Northrop Grumman and Honda
finance.yahoo.com - May 2 at 5:13 PM |
| Dinesh C. Paliwal Buys 4,770 Shares of Bristol-Myers Squibb (BMY) Stock
www.americanbankingnews.com - May 2 at 4:38 PM |
| Eli Lilly Expected to Report a Modest Rise in Revenues in 2018
finance.yahoo.com - May 2 at 8:26 AM |
| $0.85 Earnings Per Share Expected for Bristol-Myers Squibb (BMY) This Quarter
www.americanbankingnews.com - May 2 at 1:22 AM |
 | How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
www.bizjournals.com - May 1 at 5:14 PM |
| Dow Jones' Merck Slides On Mixed First Quarter As Keytruda Sales Pop
finance.yahoo.com - May 1 at 5:14 PM |
| How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
finance.yahoo.com - May 1 at 5:14 PM |
 | Ramp Up In Opdivo And Eliquis Sales Bolsters Bristol-Myers Squibb's Q1 Earnings
www.forbes.com - April 30 at 4:10 PM |
| 3 Things In Biotech, April 29: Bristol-Myers Widens, Ono Takes On Pheo, BrainStorm's ALS Adventure Moves Forward
seekingalpha.com - April 30 at 9:52 AM |
| Q2 2018 Earnings Estimate for Bristol-Myers Squibb (BMY) Issued By William Blair
www.americanbankingnews.com - April 30 at 2:14 AM |
Bristol-Myers Squibb (NYSE:BMY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Bristol-Myers Squibb (NYSE:BMY) Income Statement, Balance Sheet and Cash Flow Statement
Bristol-Myers Squibb (NYSE BMY) Stock Chart for Friday, May, 25, 2018
Loading chart…
